Key Highlights
● Total Revenue rose 7% to $8.30 billion and product sales climbed 13% to $8.29 billion.
● HIV sales grew 18% to $6.25 billion, led by Biktarvy at $4.06 billion.
● Yeztugo generated $305 million, up from $39 million a year earlier.
● The 2026 product sales forecast rose to $31.0 billion to $31.3 billion.
Gilead Sciences (NASDAQ:GILD) shares were up 5.30% at $174.39 in pre-market trading as of 8:23 a.m. ET Friday, according to pre-market data, after the biotech reported third-quarter results after Thursday's close. Another source had the stock up 5.04% earlier in the morning. A reference price heading into the session was $165.61.
The quarter that lifted the stock
Gilead is best known for its HIV medicines, but it also sells liver-disease treatments, the breast-cancer drug Trodelvy and cell therapies through its Kite unit, giving it a broader base than its HIV dependence might suggest.
Total revenue rose 7% to $8.30 billion, and product sales climbed 13% to $8.29 billion, according to the company's release. Adjusted Earnings were $2.55 a share, up from $2.47 a year earlier and ahead of the $2.17 consensus listed in a pre-week earnings calendar, which does not specify whether that figure is on an adjusted basis. GAAP earnings were $1.94 a share.
"Gilead delivered an exceptional third quarter, with our strongest year-over-year base Business growth in more than a decade," chairman and chief executive Daniel O'Day said in the release.
HIV remains the engine
The HIV Franchise did most of the work. HIV sales rose 18% to $6.25 billion, led by Biktarvy, the company's flagship daily treatment, at $4.06 billion, up 10%. Yeztugo, the lenacapavir-based HIV prevention shot, generated $305 million, up from $39 million a year earlier, an early sign that the newer long-acting product is gaining traction with doctors and payers.
On the back of those numbers, Gilead raised its 2026 product sales forecast to $31.0 billion to $31.3 billion, from $30.1 billion to $30.4 billion previously. There is a catch: the company lowered its full-year adjusted earnings guidance to a loss of $1.20 to $0.85 a share, from a loss of $0.65 to $0.30. One headline attributed the profit cut to acquisitions, which typically bring large one-time charges for acquired research projects. Investors appear to be looking past that charge to the stronger underlying sales trend.
Analysts responded positively. A brokerage reiterated its Buy rating and raised its price target to $200 from $170, according to market reports.
Index role, sector backdrop, risks and what to watch
Gilead is a member of the Nasdaq-100 and the S&P 500. Its gain stands out on a morning when Nasdaq-100 futures were down about 2.6% around 8 a.m. ET, according to market quotes, as Amazon (NASDAQ:AMZN) and Intel (NASDAQ:INTC) results deepened worries about AI spending.
Health care has been a refuge from that trade. The Health Care Select Sector SPDR fund rose 2.4% on Thursday to a record, according to market data, and was up another 1.23% pre-market Friday, according to another tracker. A pre-market snapshot at 8:23 a.m. ET showed Regeneron (NASDAQ:REGN) up 6.87%, Vertex (NASDAQ:VRTX) up 2.60% and Amgen (NASDAQ:AMGN) up 2.86%, and Sanofi (NASDAQ:SNY) was up 3.92% after its own results.
The risks are specific. Gilead depends heavily on HIV, so any pricing pressure, competition or policy change in that market matters more than for diversified peers. Section 232 pharmaceutical tariffs of up to 100% are in effect, though many companies have negotiated 15% deal rates, and Tuesday's midterm elections could change the outlook for drug pricing legislation. The Acquisition charges also mean reported earnings will look weak this year even as sales rise, and some investors may question the price paid for those deals.
Traders will watch whether the stock holds its gains after the 9:30 a.m. ET open, and for further analyst target changes. Gilead has typically reported fourth-quarter results in early February; a date was not confirmed.






Please wait processing your request...